Trial review board raises concerns about AstraZeneca vaccine data

In an unusual statement released early Tuesday, the National Institute of Allergy and Infectious Diseases said the independent board that reviews data from multiple Covid-19 vaccine candidates has raised concerns about AstraZeneca's announcement of efficacy data from its vaccine trial.

"The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," said the NIAID statement released early Tuesday.

"We urge the company to work with the DSMB to review the efficacy data and ensure the most...